Business

TScan restructures around in vivo TCR-T, pauses Phase III hematology program

Edited by Robert McTiernan··3 min read
TScan restructures around in vivo TCR-T, pauses Phase III hematology program

Waltham, Massachusetts-based TScan Therapeutics (Nasdaq: TCRX) announced a major restructuring that will shift the company away from near-term development in hematologic malignancies and toward an earlier-stage in vivo T cell receptor-engineered T cell (TCR-T) platform for solid tumors.

The reorganization will eliminate roughly 75% of TScan's workforce, close its internal manufacturing operation, and significantly reduce its research footprint. The company expects the measures to generate about USD 55 million in cumulative cost savings through the end of 2027.

As part of the restructuring, TScan will pause further enrollment in the Phase III ALLOHA-2 study of TSC-101, its allogeneic TCR-T candidate for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. Seven patients already enrolled in the treatment arm will continue to be followed.

The decision reflects financing constraints rather than a reported clinical setback. CEO Gavin MacBeath said TScan had been unable to access the capital required to complete ALLOHA-2, while pointing to continued evidence of activity from the hematology program.

TScan plans to report updated data from Cohort C of the Phase I ALLOHA study in Q4 2026, followed by a broader update in Q2 2027. All 13 patients currently being followed in Cohort C have achieved complete donor chimerism, including two patients who had previously relapsed. The company has also reported durable remissions in Cohort A.

TScan said it is seeking partners or collaborators for both its hematologic malignancy and autoimmunity programs, potentially allowing those assets to continue without drawing heavily on the company's remaining capital.

Under the revised operating plan, TScan's cash, cash equivalents, and marketable securities as of June 30, 2026 are expected to fund operations into Q4 2027.

The AllSci BriefFree, systematic R&D and deal news. Daily.

The company's remaining internal resources will be concentrated on two in vivo TCR-T candidates targeting PRAME and MAGE-A4, both of which are in IND-enabling studies. TScan expects to disclose preclinical data in Q1 2027, submit its first IND in Q3 2027, and begin Phase I development in Q4 2027.

The in vivo strategy is intended to bypass some of the practical limitations of conventional autologous TCR-T therapy, which requires patient-specific cell collection, ex vivo engineering and manufacturing, and reinfusion after lymphodepletion. TScan instead aims to engineer T cells directly in the patient.

The PRAME- and MAGE-A4-directed candidates use TCRs selected from TScan's ex vivo Phase I PLEXI-T program. The company plans initially to develop single-target therapies, with multiplexed approaches as a longer-term objective.

TScan's pivot places it in a growing field of companies attempting to generate engineered T cells directly in patients using viral or non-viral delivery technologies. Several developers are pursuing in vivo CAR-T approaches, while PRAME and MAGE-A4 are already established targets for ex vivo T cell therapies, creating a competitive benchmark for the potency and durability TScan will eventually need to demonstrate.

The restructuring therefore exchanges a more clinically advanced but capital-intensive hematology program for an earlier and less validated technology platform. Near-term evidence for the strategy will come from the Q1 2027 preclinical disclosure and the company's ability to keep its first IND filing on track for Q3 2027.

Meanwhile, further ALLOHA data and any partnership for TSC-101 will help determine how much value TScan can preserve from the hematology program while concentrating its own resources on in vivo cell therapy.

Spot something wrong? Report an issue with this article